cancer. year excited and our notable for through the today the an IkT-XXXXXX, XXXX industry updates. us patients as were us for clinical therapeutics continue XXXX neurodegenerative year we full at advance as our advance was mission and financial our continue as several and you, asset, thank recent scientific Alex clinic presentations with validate underlying We to bring Thank mechanism in all review to lead diseases and business joining well to you disease-modifying to results important living to further and conferences. to
FDA clinical program pleased diligently the hold to last XXXXXX January. IIa programs our on are lifted, XXX the Parkinson's was With trial Phase challenge, with the that While our we agency that to restart an hold had we hold unexpected in on agreed-upon amendments. lifted were announce year the clinical working
the of formulation that FDA the treat it Stable-Phase the for lifted prodrug In future of of imatinib the Atrophy, equivalence X hold System a program planning our XXX dose the finding in the IkT-XXXXXX study Simultaneously, II which Multiple Phase escalation and March, for and anticipated open mesylate year. IkT-XXXPro of second is treatment quarter has MSA. the intended on completed IND, this clinical or bioequivalent MSA a of Chronic enabling or and X dose close dose cohorts to will be Leukemia Myologic by completed is trial
proceeds. completed our make work we As by which approximately gross in million cash another recently and to $XX offering reserves placement of private clinical concurrent we a registered execution, bolstered aggregate year direct XXXX
addition to funds, of of these clinical quarter are advance fourth the well XXXX the key With through we in programs milestones. our capitalized
c-Abl IkT-XXXXXX with Kinases, Now, programs. Tyrosine to IkT-XXXXXX update selective inhibitor. first nonreceptor is let our Abelson an me our or start
and in in protein pathology shown was disease. slow roughly the of As the GI progression, diagnoses most protect has we of restore progression XX,XXX tract U.S. Parkinson's halt or available devastating published neurodegenerative this in and and there in new with the and currently disease year, studies. U.S. Today, one no in clear year is disease that diseases the each of IkT-XXXXXX brain are underlying to the halt the shown neurons January been this animal lost as options
for Parkinson's disorders. therapy on further the expand Let me and of a related disease-modifying potential as IkT-XXXXXX
administration these progression, animal to progression patients and studies showed data for of human from were recovery, in with the Parkinson's clinical IkT-XXXXXX of disease. pathology. models of XX a daily protect development the lifespan protect observed support drive disease disease-modifying protein Initiation Medicine this oral reduction January in Journal features relative IkT-XXXXXX substantial neurons Science These We IkT-XXXXXX basis neurons to studies disease. model in to in once Parkinson's rate year, mimic the from functional These that potential and was belief on highlights our disease the published Our able therapy of which and for in -- degradation. of continues correlated animal IkT-XXXXXX that aggregate of underlying the form as believe halt data
submitted Turning announce to of that neurology. Despite the decision in to in in we hold the year, lifted our pleased The program. on unexpected XXX the the FDA response the last IkT-XXXXXX division were Parkinson's the to which clinical now complete letter to we on had January. the raised December full hold based our in FDA setback issues
the of fundus of In the macula The pharmacokinetics pathology the part been response, our and of profile protein in acuity the ocular volunteers implementing has we cornea data and completed requested program dose XXX-milligram analysis anticipate and lens in with the already healthy programs is the top the planned the in to monitoring the dose set the XXX within agreed the FDA the before complement in and marketed kinase was itself. trial now we FDA submitting further visual of trial. that X pharmacokinetic measurement measure of monitoring up ocular the monitoring consistent coming the This to other days. program the study of inhibitors. This retina, to examination
observed the any to clinically emphasize patients trial no ocular been any steps to in any IkT-XXXXXX or last began are the approximately date, administered week. to completed date that patient observed and XX having duration also XX start once we to given participant pathology that adverse daily. to want first planned XX have healthy screening and dose has IkT-XXXXXX opened no patients, Parkinson's With already events screenings of several of We meaningful up sites subject been weeks dose at pleased in of
the of XXX enrollment trial second status in later will update the the We quarter.
also excited with recent the we similar essential MSA journal, previously rapidly Neurobiology forward of Multiple program rare, alpha-synuclein hold neurodegenerative Atrophy, that System disorder and the that in the in and is In autonomic also described tyrosine or clinical MSA to XX a occurs in nervous systems. movement in what of lift moving published both FDA. Parkinson's. XXXX, that progressive manner has the We're our activation is to MSA, by be following affects a c-Abl phosphorylation Disease at IkT-XXXXXX
to our a for Day trial. that planning continue we Phase efforts recent R&D encourage during our Our ongoing animal studies model future II discussed
Turning now bioequivalent study to of an IkT-XXXPro. update of our XXX
enhance arise recall, As with commonly taken for tract. the kinase which located hematological the of and XXXPro cancers imatinib or prodrug in mesylate patients mutations intended safety imatinib formulation you Chronic gastrointestinal might to tolerability Imatinib stable and Myelogenous Leukemia from of is GI in or is our marrow CML. Abl bone
dose. be And subjects comprised We and bioequivalence ages X of part our to that IkT-XXXPro safer chronic study. bioequivalent the dosing X healthy patients XX have alternative the potential X-part identify of X XX the been between for doses intent the completed tolerated XXX first cohorts better disease. is XX. with to already escalating is are whether and to across in of a a evaluating study The trial therapy control the has on their imatinib
standard the confirm dose over patient-reported X-period of metrics measured will additional superiority second crossover the as of evaluate bioequivalent The will volunteers study. and adverse healthy study phase study event using outcomes of XX the in This a also profile care.
identify the are We as of the to such evaluation contemplating milligrams further dose and equivalent safety of XXXPro high amplify differences dose potential the and imatinib tolerability prodrug. of as in imatinib delivered to high-dose XXX
now Joe Chief Frattaroli, over review to financials. to I call would turn our Financial Joe? like the Officer, the to
